Nanobiotix, a nano-medicine pioneer, continues to grow at a phenomenal rate. The French bio-tech firm has just raised €91 million on the American market, for a total of €195 million since it was founded in 2003.

The company develops revolutionary therapeutic approaches to cancer treatment. Among others, it has come up with an innovative method for focusing X rays toward cancerous tumors. This French jewel’s goal is to make nanophysics a game-changer for radiotherapy patients. Their nanotechnology- and physics-based therapeutic innovations have been overturning conventional approaches, which are generally based on either biology or chemistry.To that end, it markets a product called NBTXR3, which has been tested on a growing number of types of cancer. This has shown that nanoparticles do indeed boost the effect of radiotherapy on patients with soft-tissue sarcoma, a rare type of cancer. The product is currently being used in 13 clinical trials in different parts of the world.

In the beginning, the idea was to use nanoparticles’ physical properties to potentiate the effects of radiotherapy. Although that notion was no more than a hypothesis in the early 2000s, it has proven its worth by now.

While oncology will continue to be the priority, Nanobiotix also intends to explore nanoparticles’ potential in other therapeutic fields, including central nervous system treatments. In 2019, they created a subsidiary, Curadigm, to explore nanoparticles’ capacity to improve certain medications’ bioavailability, thereby increasing their advantages and reducing their side effects.